Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | exodeoxyribonuclease III family protein | 0.0018 | 0.102 | 0.102 |
Loa Loa (eye worm) | TKL/MLK/TAK1 protein kinase | 0.0091 | 0.6082 | 0.6082 |
Toxoplasma gondii | exonuclease III APE | 0.0018 | 0.102 | 1 |
Echinococcus granulosus | 3'partial|mitogen activated protein kinase kinase kinase | 0.0089 | 0.5934 | 0.5934 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0.102 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0.102 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0018 | 0.102 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0018 | 0.102 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0018 | 0.102 | 1 |
Echinococcus multilocularis | muscleblind protein | 0.0147 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase kinase kinase | 0.0091 | 0.6082 | 0.6082 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0018 | 0.102 | 1 |
Echinococcus multilocularis | kinase protein | 0.0089 | 0.5934 | 0.5934 |
Echinococcus granulosus | 5'partial|3'partial|mitogen activated protein kinase kinase kinase | 0.0089 | 0.5934 | 0.5934 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0018 | 0.102 | 0.102 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0018 | 0.102 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0018 | 0.102 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase 7 | 0.0089 | 0.5934 | 0.5934 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0018 | 0.102 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0018 | 0.102 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0018 | 0.102 | 0.102 |
Echinococcus multilocularis | muscleblind protein 1 | 0.0147 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0089 | 0.5934 | 0.5934 |
Brugia malayi | Protein kinase domain containing protein | 0.0091 | 0.6082 | 0.6082 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0018 | 0.102 | 0.102 |
Onchocerca volvulus | 0.0004 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0147 | 1 | 1 |
Onchocerca volvulus | 0.0004 | 0 | 0.5 | |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0018 | 0.102 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0018 | 0.102 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0147 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0018 | 0.102 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0.102 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0018 | 0.102 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0089 | 0.5934 | 0.5934 |
Echinococcus multilocularis | kinase protein | 0.0089 | 0.5934 | 0.5934 |
Echinococcus granulosus | muscleblind protein | 0.0147 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0.102 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0089 | 0.5934 | 0.5934 |
Onchocerca volvulus | Putative neutral sphingomyelinase | 0.0004 | 0 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0091 | 0.6082 | 0.6082 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.